Raymond James Financial upgraded shares of CVS Health (NYSE:CVS) from an outperform rating to a strong-buy rating in a research note published on Thursday, January 4th, MarketBeat reports. Raymond James Financial currently has $90.00 target price on the pharmacy operator’s stock. The analysts noted that the move was a valuation call.

A number of other equities research analysts also recently weighed in on CVS. ValuEngine downgraded shares of CVS Health from a buy rating to a hold rating in a research note on Sunday, December 31st. Royal Bank of Canada initiated coverage on shares of CVS Health in a research note on Tuesday, September 19th. They issued an outperform rating and a $95.00 target price on the stock. Jefferies Group set a $86.00 price target on shares of CVS Health and gave the stock a hold rating in a research report on Wednesday, October 18th. Robert W. Baird set a $77.00 price target on shares of CVS Health and gave the stock a hold rating in a research report on Monday, December 4th. Finally, Leerink Swann reiterated an outperform rating and set a $85.00 price target (down previously from $90.00) on shares of CVS Health in a research report on Tuesday, November 7th. Two research analysts have rated the stock with a sell rating, eight have issued a hold rating, eleven have assigned a buy rating and three have given a strong buy rating to the company’s stock. The stock currently has a consensus rating of Buy and an average target price of $88.06.

How to Become a New Pot Stock Millionaire

CVS Health (CVS) opened at $83.63 on Thursday. CVS Health has a 52-week low of $66.45 and a 52-week high of $84.00. The company has a market cap of $83,075.48, a P/E ratio of 17.28, a PEG ratio of 1.29 and a beta of 0.90. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.05 and a quick ratio of 0.55.

CVS Health (NYSE:CVS) last announced its earnings results on Monday, November 6th. The pharmacy operator reported $1.50 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.49 by $0.01. CVS Health had a net margin of 2.77% and a return on equity of 16.96%. The business had revenue of $46.18 billion for the quarter, compared to analyst estimates of $46.17 billion. During the same quarter in the previous year, the firm posted $1.64 earnings per share. CVS Health’s revenue was up 3.5% compared to the same quarter last year. sell-side analysts forecast that CVS Health will post 5.88 EPS for the current year.

The firm also recently declared a quarterly dividend, which will be paid on Friday, February 2nd. Investors of record on Wednesday, January 24th will be paid a $0.50 dividend. This represents a $2.00 dividend on an annualized basis and a yield of 2.39%. The ex-dividend date of this dividend is Tuesday, January 23rd. CVS Health’s dividend payout ratio (DPR) is presently 41.32%.

In related news, EVP Lisa Bisaccia sold 29,445 shares of the stock in a transaction on Thursday, December 21st. The stock was sold at an average price of $75.00, for a total value of $2,208,375.00. Following the sale, the executive vice president now owns 15,556 shares in the company, valued at approximately $1,166,700. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 0.61% of the stock is currently owned by corporate insiders.

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Jackson Grant Investment Advisers Inc. increased its position in shares of CVS Health by 0.6% in the second quarter. Jackson Grant Investment Advisers Inc. now owns 2,881 shares of the pharmacy operator’s stock worth $232,000 after purchasing an additional 18 shares during the period. Elefante Mark B boosted its stake in CVS Health by 0.7% in the second quarter. Elefante Mark B now owns 6,400 shares of the pharmacy operator’s stock valued at $515,000 after buying an additional 45 shares in the last quarter. Traynor Capital Management Inc. boosted its stake in CVS Health by 1.3% in the second quarter. Traynor Capital Management Inc. now owns 3,676 shares of the pharmacy operator’s stock valued at $290,000 after buying an additional 48 shares in the last quarter. Sequoia Financial Advisors LLC boosted its stake in CVS Health by 0.8% in the second quarter. Sequoia Financial Advisors LLC now owns 6,406 shares of the pharmacy operator’s stock valued at $515,000 after buying an additional 53 shares in the last quarter. Finally, Brookstone Capital Management boosted its stake in CVS Health by 1.8% in the second quarter. Brookstone Capital Management now owns 3,153 shares of the pharmacy operator’s stock valued at $254,000 after buying an additional 55 shares in the last quarter. Institutional investors own 81.64% of the company’s stock.

WARNING: “CVS Health (CVS) Upgraded at Raymond James Financial” was first reported by Marea Informative and is owned by of Marea Informative. If you are accessing this report on another site, it was illegally stolen and reposted in violation of United States and international copyright and trademark legislation. The legal version of this report can be viewed at https://www.mareainformativa.com/2018/01/30/cvs-health-cvs-upgraded-at-raymond-james-financial-updated-updated-updated.html.

About CVS Health

CVS Health Corporation, together with its subsidiaries, is an integrated pharmacy healthcare company. The Company provides pharmacy care for the senior community through Omnicare, Inc (Omnicare) and Omnicare’s long-term care (LTC) operations, which include distribution of pharmaceuticals, related pharmacy consulting and other ancillary services to chronic care facilities and other care settings.

Analyst Recommendations for CVS Health (NYSE:CVS)

Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.